Intellectual Property - August 24, 2022
Ultimovacs strengthens IP portfolio
Ultimovacs has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s US application for a patent covering methods for eliciting a T cell immune response with the UV1 universal cancer vaccine. Subject to grant formalities, the company expects that the patent will issue with a […]
Biotech Business - April 25, 2022
Ultimovacs receives Notice of Allowance on US Patent
Ultimovacs has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application on the use of vaccine-checkpoint inhibitor combinations to treat cancer. Subject to grant formalities, it is expected that a patent will issue with a patent term up to at least June 2037. Ultimovacs has […]
Clinical Trials - February 7, 2022
Ultimovacs progresses to last cohort in Phase I trial
Ultimovacs has completed treatment of the second dose cohort in the Phase I TENDU trial. The study is designed to evaluate the company’s Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer. Encouraging results The Drug Safety Monitoring Board (DSMB), a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns related to the first two dose cohorts. A […]
Clinical Trials - December 15, 2021
First patient enrolled in Ultimovacs’ DOVACC trial
Ultimovacs has announced that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer. DOVACC is organized with two influential European networks of gynaecological oncologists; the Nordic Society […]
Biotech Business - December 3, 2021
Ultimovacs granted Orphan Drug Designation by FDA
Ultimovacs has announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma. UV1, as add-on therapy to checkpoint inhibitors ipilimumab and nivolumab, is currently being studied as first-line treatment for metastatic melanoma in a Phase […]
Clinical Trials - November 16, 2021
Ultimovacs announces new data
Ultimovacs has announced data showing that the company’s universal cancer vaccine UV1 in combination with ipilimumab induces dynamic, multi-functional T cell responses in patients with melanoma, with the potential for protection of 5 years or more. The data will be presented as a poster at the Society For Immunotherapy of Cancer’s 36th Annual Meeting (SITC2021) […]
